CDSCO Publishes Alert For Failed Samples Of September 2024

New Delhi:  The CDSCO has published three lists of products declared as Not of Standard Quality (NSQ) and Spurious for September 2024. All these three lists were published on October 24, 2024.

These lists are as follows:

  1. Dugs analyzed by CDSCO/ central laboratories,
  2. Drugs that have been analyzed by state laboratories, and
  3. Drugs, Medical Devices, Vaccine and Cosmetics declared as Spurious/Adulterated/Misbranded

Not of Standard Quality (NSQ) drugs refer to drugs that fail to meet quality standards or specifications. The term ‘standards of quality’ is defined in the Drugs & Cosmetics Act, 1940, to mean that the drug complies with the standards set out in the Second Schedule of the said Act.

Central Laboratories NSQ List of drugs/ products

The NSQ drug list for central CDSCO laboratories specifies a total of 49 drugs that were detected to be deficient.

Out of the 49 NSQ drugs from CDSCO/Central Laboratories, 19 were reported by Central Drug Laboratory (CDL), Kolkata; 9 were reported by Regional Drugs Testing Laboratory (RDTL), Chandigarh; 15 were reported by RDTL, Guwahati; 5 were reported by Central Drugs Testing Laboratory (CDTL), Mumbai and 1 was reported by CDTL, Hyderabad.

State Laboratories NSQ List of drugs/ products

The NSQ drug list specifies a total of 18 drugs that were detected to be deficient by the state laboratories. All of these 18 drugs were declared to be not of standard quality.

Out of these 18 drugs, 15 were reported by Drugs Testing Laboratory Thiruvananthapuram and 3 was reported by Jammu and Kashmir.

It is pertinent to note that CDSCO did not receive NSQ data as per Format & in EXCEL SHEET from State Drugs Licensing Authorities of Karnataka (PDF format), Thiruvanthapuram (Excel format), and Jammu Kashmir (Excel Format) for the Month of September, 2024.

However, the State Drugs Licensing Authorities of Arunachal Pradesh, Assam, Bihar, Chhattisgarh, Goa, Gujarat, Haryana, Himachal Pradesh, Manipur, Rajasthan, Meghalaya, Mizoram, Nagaland, Odisha, Punjab, Sikkim, Tamil Nadu, Pondicherry, Telangana, Delhi, Uttarakhand, West Bengal, Andaman & Nicobar, Dadar and Nagar Haveli; Daman and Diu, Lakshadweep have not submitted any data in respect of the Not of Standard Quality (NSQ) Alert for the Month of August, 2024.

Drugs, Medical Devices, Vaccine and Cosmetics declared as Spurious/Adulterated/Misbranded

This list specifies a total of 4 drugs. All 4 drugs were detected to be spurious by the actual manufacturers of the claimed drugs. The Drugs Inspector, Odisha; Drugs Inspector, EZ, Kolkata; Drugs Inspector, Bihar; and Drugs Inspector, NZ, Ghaziabad were responsible for drawing these drugs.

All of these drugs are subject to ongoing investigation.

Related Posts

  • Pharma
  • February 11, 2025
  • 110 views
Nifty Pharma drops over 2%, 19 index stocks tumble up to 7%. What triggered this fall?

Stock Market Today: Indian pharma stocks faced significant selling pressure in today’s session, February 10, driven by weak earnings in select companies and fears that former U.S. President Donald Trump…

  • Pharma
  • February 11, 2025
  • 76 views
Glenmark secures MHRA approval to launch Winlevi in the UK

Glenmark Pharmaceuticals (Glenmark) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi in the United Kingdom. The topical treatment for acne vulgaris is approved…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Nifty Pharma drops over 2%, 19 index stocks tumble up to 7%. What triggered this fall?

Nifty Pharma drops over 2%, 19 index stocks tumble up to 7%. What triggered this fall?

Glenmark secures MHRA approval to launch Winlevi in the UK

Glenmark secures MHRA approval to launch Winlevi in the UK

Drug association ties up with NIPER to set up pharma research centre in Baddi

Drug association ties up with NIPER to set up pharma research centre in Baddi

India’s Pharma Industry: Poised for Global Expansion by 2030

India’s Pharma Industry: Poised for Global Expansion by 2030